Navigation Links
Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience

PRINCETON, N.J., Jan. 25 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Steven Leventer, Ph.D. has been appointed Vice President, Clinical Research Neuroscience.

"We are very pleased to have Steve join PharmaNet Development Group," commented Dalvir Gill, Chief Operating Officer, Late Stage Development. "Steve is a recognized expert in the fields of clinical trial design and clinical development planning. His combination of neuroscience expertise and dedication to efficiency and quality provides the right complement to our existing organization."

Dr. Leventer has over twenty years of experience in all phases of drug development. He has spent most of his career leading clinical teams at large global pharmaceutical and contract research organizations in the development of therapeutics for Alzheimer's disease, schizophrenia, depression and other central nervous system diseases. He was trained as a neurochemist and has had post-doctoral fellowships and faculty appointments at the University of Texas, Western Psychiatric Institute and Clinic, and Loyola University Stritch School of Medicine.  

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at  

    Contact: Anne-Marie Hess
    Phone: (609) 951-6842

SOURCE PharmaNet Development Group, Inc.



SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza
2. Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor
3. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
4. CooperVision Adds Global Professional Relations Role; Richard Clompus Joins Company as Vice President
5. Professor Riccardo Lencioni Joins Delcath Systems Scientific Advisory Board
6. Royalty Pharma Announces that Alexander von Perfall Joins Management Team
7. Howard Goldstein Joins Microchip Biotechnologies, Inc. as Executive Vice President
8. Scott Glenn Joins Exagen Diagnostics as Chairman and CEO
9. PFC Pharma Joins DATATRAKs CRO Connect Program
10. William Cork Joins Fenwal as Chief Technology Officer
11. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
Post Your Comments:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):